Human IL-28B Protein: Mechanisms of Antiviral Immunity and Inflammatory Regulation

Concept: Human IL-28B Protein and Its Biological Identity

Interleukin-28B (IL-28B), also known as interferon-λ3 (IFN-λ3), is a pivotal member of the interferon lambda (IFN-λ) cytokine family, a unique class of cytokines that amalgamate the structural and functional traits of both interferons and interleukins. As a secreted glycoprotein with a molecular weight of approximately 20-25 kilodaltons, IL-28B features a characteristic three-dimensional helical bundle structure formed by multiple α-helices—this structural architecture underpins its high-affinity and selective binding to cell surface receptors. Distinct from type I interferons, IL-28B possesses a unique receptor system and downstream signaling cascade, endowing it with non-redundant roles in antiviral defense and immune homeostasis. Expressed in a tissue-specific and inducible manner, IL-28B is a key modulator of innate and adaptive immunity, bridging antiviral responses and inflammatory regulation, and emerging as a promising therapeutic target for viral diseases and immune-related disorders.

Research Frontiers of IL-28B in Antiviral Immunity and Inflammation
The research landscape of IL-28B is rapidly expanding, with cutting-edge investigations focusing on unraveling the fine-tuned molecular mechanisms underlying its dual roles in antiviral immunity and inflammatory modulation, as well as its translational potential in clinical therapy. A core research frontier is the dissection of the context-dependent immunomodulatory functions of IL-28B—how it switches between anti-inflammatory and pro-inflammatory effects in different microenvironments, and the key molecular regulators governing this functional plasticity. Contemporary studies also delve into the comparative analysis of IL-28B and type I interferons, exploring the complementary and independent antiviral pathways they mediate, and the biological significance of their functional divergence in viral clearance and immune pathology.

Another critical research direction is the exploration of IL-28B’s genetic polymorphism and its clinical implications, particularly its well-documented association with treatment response in chronic viral infections such as hepatitis C. Researchers are also investigating the therapeutic potential of IL-28B and its analogs in a broader spectrum of viral diseases, including hepatitis B, influenza, and emerging viral pathogens, with a focus on developing targeted therapies that leverage IL-28B’s unique antiviral profile and potentially reduced side effects compared to traditional interferon-based treatments. Additionally, emerging research is uncovering IL-28B’s novel roles in the tumor immune microenvironment and autoimmune diseases, expanding its application beyond antiviral immunity to cancer immunotherapy and inflammatory disorder intervention.

 

Research Significance of IL-28B Study
Unraveling the mechanisms of IL-28B-mediated antiviral immunity and inflammatory regulation holds profound scientific and translational significance for immunology research, viral disease treatment, and the development of novel immunotherapeutics.

In basic immunology research, IL-28B serves as a key model molecule for understanding the functional diversity of the IFN-λ family and the intricate crosstalk between innate and adaptive immunity. Studies on IL-28B’s unique receptor signaling and context-dependent immunomodulation deepen our understanding of immune homeostasis and the molecular basis of immune response fine-tuning, filling critical gaps in the knowledge of cytokine-mediated immune regulation. Furthermore, comparative studies between IL-28B and type I interferons shed light on the evolutionary adaptation of the immune system to viral infections, providing new insights into the design of targeted antiviral immune strategies.

Translationally, IL-28B research has already revolutionized the clinical management of chronic hepatitis C, with its genetic polymorphisms established as a crucial predictive biomarker for interferon-based therapy response—this has enabled personalized treatment stratification and improved clinical outcomes for patients. Beyond hepatitis C, IL-28B represents a novel therapeutic target for a wide range of viral diseases, with its direct antiviral activity and unique immunomodulatory profile offering an alternative to traditional interferons, which are often associated with severe side effects. Additionally, the emerging roles of IL-28B in tumor immunity and autoimmune diseases open new avenues for the development of immunotherapies that modulate the immune microenvironment, addressing unmet clinical needs in cancer treatment and inflammatory disorder management. For the biopharmaceutical industry, IL-28B research drives the development of novel biologics, including recombinant IL-28B proteins, receptor agonists/antagonists, and cytokine-based combination therapies, fueling innovation in antiviral and immunotherapeutic drug development.

Mechanisms, Regulatory Functions and Product Applications
Biosynthesis, Tissue Distribution and Core Biological Functions of IL-28B

Biosynthesis and In Vivo Distribution
IL-28B biosynthesis is a tightly regulated process initiated by gene transcription in specialized immune cells, primarily dendritic cells and macrophages—key antigen-presenting cells of the innate immune system. IL-28B messenger RNA (mRNA) is transcribed in the nucleus, followed by cytoplasmic translation to generate precursor proteins, which undergo post-translational modifications (notably glycosylation) to form fully bioactive mature IL-28B molecules that are secreted into the extracellular milieu.

Under physiological conditions, IL-28B exhibits tissue-specific distribution, predominantly localized in tissues with abundant immune cells and the extracellular matrix. Its expression is highly inducible: during viral infection or local inflammation, IL-28B expression is markedly upregulated in parenchymal tissue cells and infiltrating immune cells at the site of injury/infection, a hallmark of its rapid recruitment into the local immune defense and regulatory network.

Core Physiological Functions: Antiviral Immunity and Immune Modulation
IL-28B exerts dual core functions centered on direct antiviral activity and indirect immunomodulatory effects, synergistically mediating host defense against viral pathogens while maintaining immune balance:
1. Direct antiviral activity: IL-28B binds to its specific cell surface receptor on virus-infected cells, activating classical intracellular antiviral signaling pathways. This induces the expression of key antiviral effector proteins, including double-stranded RNA-dependent protein kinase (PKR) and 2',5'-oligoadenylate synthetase (OAS), which directly inhibit viral genome replication and protein synthesis, establishing a cell-intrinsic antiviral state that restricts viral spread.
2. Indirect immunomodulatory effects: IL-28B potentiates both innate and adaptive antiviral immunity. It activates natural killer (NK) cells, enhancing their cytotoxic activity against virus-infected target cells; it also modulates T lymphocyte differentiation and function, promoting the development of antiviral Th1 cells and regulating cytotoxic T lymphocyte (CTL) responses. These effects collectively amplify the host’s adaptive antiviral immune response, facilitating efficient viral clearance.

Context-Dependent Inflammatory Regulation and Molecular Action Mechanism
Fine-Tuned Inflammatory Regulation by IL-28B
IL-28B’s immunomodulatory effects are characterized by context-dependent complexity, with the ability to exert both anti-inflammatory and pro-inflammatory roles based on the local immune microenvironment:
· Immune balance maintenance: IL-28B promotes Th1-type immune responses while inhibiting excessive Th2 cell differentiation, preventing immune response bias and maintaining a balanced cellular and humoral immunity—this is critical for avoiding ineffective antiviral responses or pathological humoral immunity.
· Dual inflammatory modulation: In the setting of excessive inflammation, IL-28B suppresses the overproduction of pro-inflammatory cytokines (e.g., IL-6), mitigating inflammatory tissue damage and immune pathology; during the early stages of viral infection, it activates immune cells and induces inflammatory chemokines, moderately enhancing local inflammation to recruit immune cells and facilitate pathogen clearance. This microenvironment-dependent fine-tuning makes IL-28B a key regulator of immune homeostasis.

Molecular Mechanism of IL-28B Action: The JAK-STAT Signaling Pathway
The biological functions of IL-28B are mediated by a highly conserved JAK-STAT signaling pathway, initiated by its binding to a specific heterodimeric cell surface receptor composed of the IL-28 receptor α-chain (IL-28Rα) and the interleukin-10 receptor β-chain (IL-10Rβ):
1. Receptor binding and activation: IL-28B binding induces a conformational change in the IL-28Rα/IL-10Rβ heterodimer, activating Janus kinases (JAKs) associated with the receptor’s intracellular domain.
2. STAT phosphorylation and dimerization: Activated JAKs phosphorylate signal transducer and activator of transcription (STAT) proteins (predominantly STAT1, STAT3, and STAT5). Phosphorylated STAT proteins undergo homo- or heterodimerization, a critical step for their nuclear translocation.
3. Nuclear transcription and effector gene expression: STAT dimers translocate to the nucleus, where they bind to specific DNA response elements in the promoter regions of antiviral and immunoregulatory genes, initiating or enhancing their transcription. This cascade ultimately drives the expression of antiviral effector proteins and immune modulatory factors, mediating IL-28B’s antiviral and inflammatory regulatory functions.

Clinical Application Prospects of IL-28B
IL-28B has demonstrated compelling clinical application potential, with the most mature research and application in viral disease treatment, and emerging prospects in tumor immunology and autoimmune disease intervention:
1. Hepatitis C therapy: IL-28B gene polymorphisms are a well-validated genetic biomarker for predicting patient response to pegylated interferon-α and ribavirin combination therapy for chronic hepatitis C, enabling personalized treatment selection and improving therapeutic efficacy.
2. Novel antiviral therapeutics: Recombinant IL-28B or its analogs represent a promising novel antiviral therapy, with their unique receptor tropism and reduced side effect profile compared to type I interferons making them an attractive alternative for chronic viral infection treatment (e.g., hepatitis B, influenza).
3. Tumor immunotherapy: Emerging studies reveal that IL-28B modulates the tumor immune microenvironment by regulating the activity of NK cells, T cells, and antigen-presenting cells, with potential applications in enhancing anti-tumor immune surveillance and sensitizing tumors to immunotherapy.
4. Inflammatory and autoimmune disease intervention: IL-28B’s anti-inflammatory effects in specific microenvironments make it a potential therapeutic target for autoimmune diseases (e.g., systemic lupus erythematosus, multiple sclerosis) and chronic inflammatory disorders, by mitigating excessive inflammatory damage and restoring immune homeostasis.

ANT BIO PTE. LTD. – Empowering IL-28B Research with High-Quality Recombinant Protein
As a global leader in life science reagents, ANT BIO PTE. LTD. leverages its advanced recombinant protein development platform under the UA sub-brand (specializing in high-purity, bioactive recombinant proteins) to independently develop the Human IL-28B Protein, His tag (Catalog No.: S0A4057)—a high-performance recombinant IL-28B (IFN-λ3) protein with superior bioactivity, ultra-high purity, and exceptional stability. Expressed in the HEK293 mammalian cell system (a gold standard for recombinant protein production) with an N- or C-terminal His tag, this product faithfully recapitulates the native structural and functional characteristics of human IL-28B, serving as an indispensable research tool for unraveling IL-28B’s mechanisms in antiviral immunity, inflammatory regulation, tumor immunology, and the development of novel biologics.

Core Advantages of ANT BIO PTE. LTD.’s Human IL-28B Protein, His tag (S0A4057)
 

Core Advantages	Detailed Product Characteristics
Native Conformation and Superior Bioactivity	Expressed in the HEK293 mammalian expression system, ensuring correct protein folding, physiological glycosylation, and disulfide bond formation—mimicking the native structure of endogenous human IL-28B. Bioactivity is rigorously validated via ISRE luciferase reporter gene assays, demonstrating robust activation of the JAK-STAT signaling pathway comparable to endogenous IL-28B.
Ultra-High Purity and Low Endotoxin	Purified through a multi-step chromatographic process (affinity + size-exclusion chromatography), achieving >95% purity confirmed by SDS-PAGE and HPLC. Endotoxin levels are strictly controlled below 1.0 EU/μg, eliminating non-specific immune activation and making the product suitable for sensitive in vitro cell experiments and in vivo animal studies.
Exceptional Stability and Batch-to-Batch Consistency	Manufactured under stringent quality control (QC) standards, with minimal intra- and inter-batch variation in physicochemical properties and bioactivity. The product exhibits outstanding stability during storage and transportation, providing reliable and reproducible protein material for long-term research projects and large-scale drug screening.
Flexible His Tag Design	Equipped with an N- or C-terminal His tag that enables rapid, high-efficiency purification via immobilized metal ion affinity chromatography (IMAC). The tag also facilitates easy detection, labeling, and further conjugation of the protein, supporting diverse experimental applications.

Key Application Scenarios for S0A4057 Human IL-28B Protein, His tag
1. Antiviral Immunity Research: Investigate the role of IL-28B/IFN-λ signaling in host defense against hepatitis viruses (HCV, HBV), influenza, and emerging viral pathogens; conduct comparative studies on IL-28B and type I interferon-mediated antiviral pathways.
2. Tumor Immune Microenvironment Research: Explore IL-28B’s direct/indirect effects on tumor cells and immune cells (NK cells, T cells, dendritic cells); evaluate its potential in enhancing tumor immune surveillance and developing combination cancer immunotherapies.
3. Autoimmune & Inflammatory Disease Research: Study IL-28B’s anti-inflammatory and immunomodulatory roles in autoimmune diseases (lupus, multiple sclerosis) and chronic inflammatory disorders; identify its potential as a therapeutic target for restoring immune homeostasis.
4. Drug Screening & Biomarker Development: Serve as a key target molecule for high-throughput screening of IL-28Rα/IL-10Rβ receptor agonists/antagonists; act as a standard reference for the development of diagnostic reagents to detect serum IL-28B levels in clinical samples.
5. Receptor Signaling Pathway Analysis: Characterize the binding kinetics between IL-28B and its heterodimeric receptor (IL-28Rα/IL-10Rβ); unravel the molecular mechanisms of JAK-STAT pathway activation and downstream effector gene regulation mediated by IL-28B.

Comprehensive Technical Support from ANT BIO PTE. LTD.
We provide a full suite of technical documentation and professional support for the Human IL-28B Protein, His tag (S0A4057), including:
· Detailed product specifications, purity/molecular weight analysis reports, and endotoxin test results;
· Bioactivity validation data (e.g., EC50 values from reporter gene assays);
· Optimized experimental protocols for in vitro cell assays, in vivo animal studies, and receptor binding experiments;
· One-on-one professional technical consultation from our experienced team of immunology and protein biology experts, supporting experimental design, troubleshooting, and result interpretation.

Related Product List

Catalog Number	Product Name	Core Features	Key Applications	Sub-brand	Stock Status
S0A4057	Human IL-28B Protein, His tag	HEK293-expressed; >95% purity; <1.0 EU/μg endotoxin; N/C-terminal His tag; native bioactivity	Antiviral immunity research, JAK-STAT signaling analysis, drug screening	UA	In Stock
-	Human IL-28Rα Recombinant Protein, Fc tag	HEK293-expressed; high purity; bioactive; Fc tag for easy detection	IL-28B receptor binding assays, signaling pathway research	UA	In Stock
-	JAK/STAT Signaling Antibody Panel	Recombinant mAbs; high specificity; WB/IF/IHC compatible; targets JAK1/2, STAT1/3/5	IL-28B signaling pathway validation, phospho-protein analysis	Starter	In Stock
-	ISRE Luciferase Reporter Gene Assay Kit	Ready-to-use; high sensitivity; quantitative; suitable for IFN/IL-28B bioactivity detection	IL-28B bioactivity validation, antiviral drug screening	Absin	In Stock
-	Pro-Inflammatory Cytokine ELISA Kit Panel (IL-6/TNF-α/IL-1β)	High sensitivity/specificity; quantitative; ready-to-use; cell culture supernatant/serum compatible	IL-28B inflammatory regulation research, therapeutic efficacy evaluation	Absin	In Stock
-	Anti-Human IL-28B Polyclonal Antibody	High affinity; specific; WB/ELISA/IF compatible	IL-28B protein detection, expression analysis in cells/tissues	Starter	In Stock

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.